Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 1, 2004, Pages 49-61

  Gugiatti, A ^a   Grimaldi, Adelmo ^b   Rossetti, C ^c   Lucignani, G ^d   De Marchis, D ^b   Borgonovi, E ^a   Fazio, F ^b  

^a BOCCONI UNIVERSITY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Lung neoplasms, diagnosis; Lung neoplasms, radionuclide imaging; Tomograpy, emission computed

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGING; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DECISION THEORY; DIAGNOSTIC IMAGING; ECONOMIC EVALUATION; EUROPE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; INTERMETHOD COMPARISON; ITALY; JAPAN; LUNG NODULE; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; PATIENT MONITORING; PNEUMOTHORAX; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PUBLIC HEALTH SERVICE; REIMBURSEMENT; RESOURCE ALLOCATION; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; UNITED STATES;

CARCINOMA, NON-SMALL-CELL LUNG; COIN LESION, PULMONARY; COST SAVINGS; COST-BENEFIT ANALYSIS; HUMANS; ITALY; LUNG NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4043155756     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Tesar R, Papatheofanis FJ, Valk PE. Reimbursement and technology assessment for positron imaging. Clin Positron Imaging 1998;1:51-8.
2. Atherly A, Culler SD, Becker ER. The role of cost effectiveness in health care evaluation. Q J Nucl Med 2000;44:112-20.
3. Gambhir SS, Schwimmer J, Phelps ME. Economic evaluation studies in nuclear medicine. A methodological review of literature. J Nucl Med 2000;44:121-37.
4. Gugiatti A. Tomografia ad emissione di positroni: aspetti diagnostici e gestionali di una tecnologia diagnostica innovativa. Mecosan 1994;9:16-24.
5. Gugiatti A, Rossetti C, Grimaldi A, Fazio F. Due esercizi di analisi decisionale sulla introduzione della PET nei noduli polmonari solitari e nello staging di pazienti con NSCLC. Mecosan 1999;31:37-48.
6. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Phelps ME, Gambhir SS. A review and meta-analysis of the literature for whole-body FDG PET in the detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-89.
7. Schwimmer J, Essner R, Shepherd JE, Park K, Silverman D, Phelps ME et al. A review of the Literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000; 44:153-67.
8. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42 (5 Suppl):1S-93S.
9. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
10. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of no-small-cell lung carcinoma. J Nucl Med 1996;37:1428-36.
11. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE et al. Analytical Decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.
12. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg.1998;66:1876-83.
13. Madar I, Hoh C, Figlin R, Holmes CE, Waters PF, Gambhir SS et al. Cost-effective staging of non small cell lung carcinoma by whole-body PET-FDG imaging. J Nucl Med 1995;36(suppl):57.
14. Tomatis L. Cancer: causes, occurrence and control. Lyon: IARC Scientific Publications 1990:100.
15. Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Esteve J. Survival of cancer patients in Europe: the EUROCARE study. Lyon: IARC Scientific Publications 1995:132.
16. Berrino F, Gatta G, Chiessa E, Valente F, Capocaccia Rl. The EUROCARE II study. Eur J Cancer 1998;34(Suppl 14):2139-53.
17. Lega Italiana per la Lotta contro i Tumori - Associazione italiana di Epidemiologia, II cancro in Italia. I dati di incidenza dei registri tumori 1983-1987. Roma: Il Pensiero Scientifico; 1992.
18. For Modena: www.usl.mo.it/pps/salute/download/tumored1.pdf
19. For Tuscany: Polo Oncologico Nord-Ovest. In: www.med.unipi.it/ chirtor/introduzione.html.for Tuscany.
20. For Sassari: www.geocities.com/Athens/Delphi/1620/incidenza.html
21. DRG 2000. Rapporto sui ricoveri Lombardia (edition of 27.07.2002) in www.sanita.regione.lombardia.it/pubblicazioni/archivio.htm
22. Herder GJ,Verboom P,Smit EF, van Velthoven PC, van der Bergh JH, Colder CD et al. Practice, efficacy, and cost of staging suspected non- small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax 2002;57:11-4.
23. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000; 27:1441-56.
24. Klose T, Leidl R, Buchmann I, Brambs H-J, Reske SN. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med 2000;27:1457-64.
25. DM 22 luglio 1996 "Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe".
26. DGR 5.11.2001 n. 2.354 for Regione Emilia Romagna.
27. DGR 23.4.1999 n. VI/42606 for Lombardy.
28. DM on "Tariffe delle prestazioni di assistenza ospedaliera" of 14 dicembre 1994.
29. DM 30.6.1997 modification of tariffs of reimbursement.
30. DGR 12287/2003 tariffs of reimbursement for Lombardy.
31. Webb W, Gatsonis C, Zerhouni E, Heelan RT, Glazer GM, Francis IR et al. Ct and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Group. Radiology 1991;178:705-13.
32. Yokoi K, Okuyama A, Mori K. Mediastinal lymph node metastasis from lung cancer: evaluation with Tl-SPECT- comparison with CT. Radiology 1994;9:37-42.
33. Seely J, Mayo J, Muller N. Tl lung lung cancer: prevalence of mediastinal nodal metastases and diagnostic accuracy of CT. Radiology 1993;186:129-32.
34. Valk P, Pounds T, Hopkins D, Haseman M, Hofer G, Greiss H. Staging lung cancer by whole-body PET-FDG imaging. J Nucl Med 1995;36(Suppl):95.
35. Beck J, Kassirer J, Pauker S. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-8.
36. Beck J, Pauker S, Gottlieb J. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982;73:889-97.
37. Dietlein M, Knapp WH, Lauterbach KW, Schicha H. Economic evaluation studies in nuclear medicine. Eur J Nucl Med 1999; 26:663-80.
38. Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Valburg W, Koeter GH et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
39. Wahl R, Quint L, Greenough R, Meyer C, White R, Orringer M. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.